(“Ananda” or the “Company”)
The directors of
The hapac® product was launched in
-- The feedback from customers is that hapac® is easy to use, practical, offers a precise dosage and is being consumed mostly in the evening; -- 80% of customers reported that the dosage is ‘just right’; -- 70% of customers said that they would be interested in a subscription service in the future; -- Initial Net Promoter Scores (“NPS”) are positive, however the sample size is insufficient to report with confidence on the results. The NPS is a well-regarded measurement for customer satisfaction. NPS is an indicator of customer’s willingness to recommend an organisation to others, usually colleagues or friends
As a result of these positive results hapac® will be launched in a further three Italian locations over the next 3 months.
The hapac® team consists of senior executives previously employed at one of the world’s big five tobacco companies. The team is highly experienced in product innovation and marketing and has developed hapac® from its understanding of the key consumer, technology and regulatory trends in the tobacco industry and their relevance to the nascent cannabis sector.
A recent report by BDS Analytics says that 69% of cannabis consumers in the US and
-- Its pre-packed sachets deliver a measured dose of medical cannabis to the user; -- The manufacture of hapac® does not require the use of potentially toxic solvents or synthetic additives; -- hapac® offers a more authentic experience, close to smoking but without the toxic effects of combustion; and -- hapac®’s patent pending sachets can be safely composted after use, making them more environmentally friendly.
Since Ananda made its investment in LHT, the global medical cannabis market has continued to expand both geographically and in size. Significantly, since
Further information on the hapac® product can be found at http://hapac.tech.
The directors of the Company accept responsibility for the contents of this announcement.
Ananda Developments plc+44 (0)739 269 6517 firstname.lastname@example.org Executive Director Melissa SturgessInvestor Relations Jeremy Sturgess-Smith Peterhouse Capital Limited+44 (0)20 7469 0930 Corporate Finance Fungai Ndoro Mark AnwylCorporate Broker Lucy Williams Duncan Vasey
Notes to editors
Ananda Developments has been established as a company to invest in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the
Ananda’s investment strategy is to invest in companies, projects or products that are either progressing medical or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.